Compares dye injection methods to find lymph nodes in endometrial cancer surgery
Compares injection points for dye to map lymph nodes in endometrial cancer.
Plain-language title generated from the registry record
Registry title: Comparison of Two-Position and Four-Position Cervical Injection Techniques for Sentinel Lymph Node Mapping in Endometrial Cancer Using Methylene Blue
Key facts
- Where
- Ankara and Izmir, TürkiyeSee the 2 sites
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for women aged 18 to 75 with stage I endometrial cancer who are having surgery. It compares two ways of injecting methylene blue into the cervix to find the sentinel lymph node.
- Age
- 18 to 75 years
- Sex
- Women only
- Disease stage
- Stage I endometrial cancer, shown on CT and PET-CT imaging and confirmed by pathology.
- Earlier treatment
- Cannot join if they had active treatment for another cancer in the past five years, or earlier pelvic lymph node removal, pelvic dissection or radiation therapy.
Main reasons for not taking part
- Dementia
- Allergy to methylene blue or iodine
- Positive lymph nodes or metastatic disease
- Advanced cervical or uterine cancer, T3/T4 lesions, or cervical tumor larger than 2 cm (0.8 in)
- Liver problems with a MELD score ≥ 10 and creatinine ≥ 2·0 mg/dl
Read by machine on 12 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Source: NCT07040657, who can take part
Where in Türkiye
- Ankara UniversityAnkara, TürkiyeContact: Salih Taskin, MDTaking people
- Dokuz Eylul UniversityIzmir, TürkiyeContact: Ibrahim Yalcin, M.D.Taking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Dokuz Eylul University
- Trial code
- NCT07040657
- Record updated
- 27 June 2025
- Original description
This clinical trial evaluates lymph node mapping in newly diagnosed endometrial cancer patients undergoing surgery. The standard technique uses a 2-point methylene blue cervical injection. The study aims to determine if increasing injection points improves mapping success.Read full original descriptionShow less
Comparison of Two-Point and Four-Point Cervical Injection Techniques Using Methylene Blue for Sentinel Lymph Node Mapping in Endometrial Cancer
This clinical trial evaluates lymph node mapping in newly diagnosed endometrial cancer patients undergoing surgery. The standard technique uses a 2-point methylene blue cervical injection. The study aims to determine if increasing injection points improves mapping success.
Inclusion: Individuals diagnosed with stage I endometrial cancer based on CT and PET-CT imaging; Individuals with a pathologically confirmed diagnosis of stage I endometrial cancer.
Exclusion: Individuals who have received active treatment for another malignancy within the past five years; Inability to successfully perform PLD (pelvic lymphadenectomy) or history of prior PLD; Medical Conditions; Individuals diagnosed with dementia; Individuals with allergies to methylene blue or iodine; Women with multiple and confluent lymph nodes identified as positive on FDG-PET/CT (such cases are not considered stage I); Cancer-Related Conditions; Individuals with clinically or radiologically identified positive lymph nodes or metastatic disease; Individuals with a history of pelvic dissection and/or radiation therapy; Individuals with advanced cervical or uterine cancer; Individuals with hepatic dysfunction and a MELD score ≥ 10 and creatinine ≥ 2·0 mg/dl patients; Individuals with T3/T4 lesions; Individuals with cervical tumors larger than 2 cm; Organ Dysfunction.